Viron Therapeutics (London, ON)

CMDF Investment: $7,004,000.00
Focus: Cardiovascular Diseases & Blood Products   Inflammatory Diseases  
www.virontherapeutics.com

Viron is a biopharmaceutical company dedicated to becoming a market leader in the treatment of inflammatory disorders. By harnessing the evolutionary power of viruses that have evolved over millennia to withstand the human body’s protective inflammatory response; the Company is developing powerful protein therapeutics that will block the human body’s inflammatory attack. The Company’s lead compound; VT-111; has recently entered Phase 2 clinical trials for the treatment of vascular inflammation in patients with Acute Coronary Syndromes and is also undergoing late preclinical studies for the treatment of transplant vasculopathy. Viron’s additional pipeline of 5 compounds in preclinical development; combined with a robust discovery program; strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory based diseases.